Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
DK3484888T3 - Faste former af ttk-inhibitor - Google Patents
[go: Go Back, main page]

DK3484888T3 - Faste former af ttk-inhibitor - Google Patents

Faste former af ttk-inhibitor Download PDF

Info

Publication number
DK3484888T3
DK3484888T3 DK17830139.6T DK17830139T DK3484888T3 DK 3484888 T3 DK3484888 T3 DK 3484888T3 DK 17830139 T DK17830139 T DK 17830139T DK 3484888 T3 DK3484888 T3 DK 3484888T3
Authority
DK
Denmark
Prior art keywords
solid forms
ttk inhibitor
ttk
inhibitor
solid
Prior art date
Application number
DK17830139.6T
Other languages
Danish (da)
English (en)
Inventor
Sze-Wan Li
Heinz W Pauls
Peter Brent Sampson
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Application granted granted Critical
Publication of DK3484888T3 publication Critical patent/DK3484888T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • C30B29/58Macromolecular compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/14Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions the crystallising materials being formed by chemical reactions in the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Metallurgy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17830139.6T 2016-07-18 2017-07-13 Faste former af ttk-inhibitor DK3484888T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662363424P 2016-07-18 2016-07-18
PCT/CA2017/050848 WO2018014116A1 (en) 2016-07-18 2017-07-13 Solid forms of ttk inhibitor

Publications (1)

Publication Number Publication Date
DK3484888T3 true DK3484888T3 (da) 2023-05-30

Family

ID=60991755

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17830139.6T DK3484888T3 (da) 2016-07-18 2017-07-13 Faste former af ttk-inhibitor

Country Status (25)

Country Link
US (3) US10584130B2 (sr)
EP (1) EP3484888B1 (sr)
JP (2) JP6961675B2 (sr)
KR (2) KR102537088B1 (sr)
CN (2) CN115093416B (sr)
AU (2) AU2017299850B2 (sr)
BR (1) BR112019000813A2 (sr)
DK (1) DK3484888T3 (sr)
ES (1) ES2945108T3 (sr)
FI (1) FI3484888T5 (sr)
HR (1) HRP20230481T1 (sr)
HU (1) HUE061872T2 (sr)
IL (1) IL264173B2 (sr)
LT (1) LT3484888T (sr)
MA (1) MA45691A (sr)
MX (2) MX385289B (sr)
PL (1) PL3484888T3 (sr)
PT (1) PT3484888T (sr)
RS (1) RS64210B1 (sr)
RU (2) RU2753905C2 (sr)
SG (2) SG10202103332UA (sr)
SI (1) SI3484888T1 (sr)
SM (1) SMT202300156T1 (sr)
TW (2) TWI824313B (sr)
WO (1) WO2018014116A1 (sr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3484888T3 (pl) 2016-07-18 2023-06-26 University Health Network Stałe postacie inhibitora TTK
KR20240175121A (ko) 2023-06-12 2024-12-19 한국재료연구원 희토류 산화물을 이용한 입계확산물질의 제조방법 및 이를 이용한 R-Fe-B계 영구자석의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100876327B1 (ko) 2001-02-21 2008-12-31 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 진단에서의, 그리고 암에서 치료 표적으로서의 ttk
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2014503521A (ja) * 2010-12-17 2014-02-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、イミダゾピラジン類
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
PL3484888T3 (pl) 2016-07-18 2023-06-26 University Health Network Stałe postacie inhibitora TTK

Also Published As

Publication number Publication date
US11878980B2 (en) 2024-01-23
KR102700233B1 (ko) 2024-08-28
SI3484888T1 (sl) 2023-07-31
HUE061872T2 (hu) 2023-08-28
US20190292193A1 (en) 2019-09-26
SG11201900113UA (en) 2019-02-27
JP6961675B2 (ja) 2021-11-05
WO2018014116A1 (en) 2018-01-25
CN109476667A (zh) 2019-03-15
SMT202300156T1 (it) 2023-07-20
US20200270259A1 (en) 2020-08-27
MX2021008658A (es) 2021-08-19
CA3030230A1 (en) 2018-01-25
MX2019000744A (es) 2019-05-02
TWI745400B (zh) 2021-11-11
CN109476667B (zh) 2022-06-28
RU2021124795A (ru) 2021-09-14
MA45691A (fr) 2019-05-22
NZ749844A (en) 2024-03-22
RU2019101109A3 (sr) 2021-02-05
RU2753905C2 (ru) 2021-08-24
LT3484888T (lt) 2023-06-12
AU2017299850A8 (en) 2019-03-21
FI3484888T3 (fi) 2023-05-03
AU2021221447A1 (en) 2021-10-07
CN115093416A (zh) 2022-09-23
KR20190029601A (ko) 2019-03-20
SG10202103332UA (en) 2021-05-28
TW201803876A (zh) 2018-02-01
KR20230074839A (ko) 2023-05-31
TWI824313B (zh) 2023-12-01
MX385289B (es) 2025-03-18
CN115093416B (zh) 2024-04-12
AU2017299850A1 (en) 2019-01-24
EP3484888A4 (en) 2020-01-08
KR102537088B1 (ko) 2023-05-25
HRP20230481T1 (hr) 2023-07-21
IL264173A (en) 2019-02-28
RS64210B1 (sr) 2023-06-30
US20220089601A1 (en) 2022-03-24
BR112019000813A2 (pt) 2019-04-30
ES2945108T3 (es) 2023-06-28
EP3484888B1 (en) 2023-02-22
FI3484888T5 (fi) 2024-02-26
IL264173B1 (en) 2025-01-01
RU2019101109A (ru) 2020-08-18
US10584130B2 (en) 2020-03-10
AU2017299850B2 (en) 2021-05-27
JP7263473B2 (ja) 2023-04-24
EP3484888A1 (en) 2019-05-22
IL264173B2 (en) 2025-05-01
AU2021221447B2 (en) 2023-09-21
PT3484888T (pt) 2023-05-26
TW202202507A (zh) 2022-01-16
JP2019521155A (ja) 2019-07-25
US11104681B2 (en) 2021-08-31
PL3484888T3 (pl) 2023-06-26
JP2022001598A (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
IL285686B (en) Crystalline solid forms of a bet inhibitor
IL263586B (en) Inhibitors of the menin-mll interaction
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
EP3458445A4 (en) KRAS G12C INHIBITORS
DK3371171T3 (da) Inhibitorer af RET
DK3377059T3 (da) Hæmmere af cxcr2
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3465098T3 (da) Detektering af objekter
DK3511319T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3431475T3 (da) Faste former af en selektiv CDK4/6-hæmmer
DK3442972T3 (da) Bromdomænehæmmere
LT3728207T (lt) Chinazolinonai kaip parp14 inhibitoriai
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
DK3533449T3 (da) SELEKTIV HÆMMER AF EXON-20-INSERTIONsMUTANT EGFR
DK3457851T3 (da) Derivater af sobetirom
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3113773T3 (da) Krystallinske former af grapiprant
IL254502A0 (en) Solid forms of menaquinols
DK3529236T3 (da) Krystalformer af eravacyclin
EP3479227A4 (en) CORRELATION OF MULTIPLE SOURCES